Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.

<h4>Background</h4>To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer.<h4>Methodology/principal findings</h4>Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneou...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yoshikane Yamauchi, Yotaro Izumi, Kohei Hashimoto, Hideki Yashiro, Masanori Inoue, Seishi Nakatsuka, Taichiro Goto, Masaki Anraku, Takashi Ohtsuka, Mitsutomo Kohno, Masafumi Kawamura, Hiroaki Nomori
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
R
Q
Acceso en línea:https://doaj.org/article/40f66a6ca3fd45b0935a10bd0cf3bbb0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:40f66a6ca3fd45b0935a10bd0cf3bbb0
record_format dspace
spelling oai:doaj.org-article:40f66a6ca3fd45b0935a10bd0cf3bbb02021-11-18T07:25:43ZPercutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.1932-620310.1371/journal.pone.0033223https://doaj.org/article/40f66a6ca3fd45b0935a10bd0cf3bbb02012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22413004/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer.<h4>Methodology/principal findings</h4>Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I lung cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered to be medically inoperable with Charlson comorbidity index of 3 or greater. Follow-up was based primarily on computed tomography. There were 22 patients with 34 tumors who underwent 25 sessions of cryoablation treatment. Complications were pneumothoraces in 7 treatments (28%, chest tube required in one treatment), and pleural effusions in 8 treatments (31%). The observation period ranged from 12-68 months, average 29±19 months, median 23 months. Local tumor progression was observed in one tumor (3%). Mean local tumor progression-free interval was 69±2 months. One patient died of lung cancer progression at 68 months. Two patients died of acute exacerbations of idiopathic pulmonary fibrosis which were not considered to be directly associated with cryoablation, at 12 and 18 months, respectively. The overall 2- and 3-year survivals were 88% and 88%, respectively. Mean overall survival was 62±4 months. Median overall survival was 68 months. The disease-free 2- and 3-year survivals were 78% and 67%, respectively. Mean disease-free survival was 46±6 months. Pulmonary function tests were done in 16 patients (18 treatments) before and after cryoablation. Percentage of predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly before and after cryoablation (93±23 versus 90±21, and 70±11 versus 70±12, respectively).<h4>Conclusions/significance</h4>Although further accumulation of data is necessary regarding efficacy, cryoablation may be a feasible option in medically inoperable stage I lung cancer patients.Yoshikane YamauchiYotaro IzumiKohei HashimotoHideki YashiroMasanori InoueSeishi NakatsukaTaichiro GotoMasaki AnrakuTakashi OhtsukaMitsutomo KohnoMasafumi KawamuraHiroaki NomoriPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 3, p e33223 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Yoshikane Yamauchi
Yotaro Izumi
Kohei Hashimoto
Hideki Yashiro
Masanori Inoue
Seishi Nakatsuka
Taichiro Goto
Masaki Anraku
Takashi Ohtsuka
Mitsutomo Kohno
Masafumi Kawamura
Hiroaki Nomori
Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.
description <h4>Background</h4>To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer.<h4>Methodology/principal findings</h4>Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I lung cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered to be medically inoperable with Charlson comorbidity index of 3 or greater. Follow-up was based primarily on computed tomography. There were 22 patients with 34 tumors who underwent 25 sessions of cryoablation treatment. Complications were pneumothoraces in 7 treatments (28%, chest tube required in one treatment), and pleural effusions in 8 treatments (31%). The observation period ranged from 12-68 months, average 29±19 months, median 23 months. Local tumor progression was observed in one tumor (3%). Mean local tumor progression-free interval was 69±2 months. One patient died of lung cancer progression at 68 months. Two patients died of acute exacerbations of idiopathic pulmonary fibrosis which were not considered to be directly associated with cryoablation, at 12 and 18 months, respectively. The overall 2- and 3-year survivals were 88% and 88%, respectively. Mean overall survival was 62±4 months. Median overall survival was 68 months. The disease-free 2- and 3-year survivals were 78% and 67%, respectively. Mean disease-free survival was 46±6 months. Pulmonary function tests were done in 16 patients (18 treatments) before and after cryoablation. Percentage of predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly before and after cryoablation (93±23 versus 90±21, and 70±11 versus 70±12, respectively).<h4>Conclusions/significance</h4>Although further accumulation of data is necessary regarding efficacy, cryoablation may be a feasible option in medically inoperable stage I lung cancer patients.
format article
author Yoshikane Yamauchi
Yotaro Izumi
Kohei Hashimoto
Hideki Yashiro
Masanori Inoue
Seishi Nakatsuka
Taichiro Goto
Masaki Anraku
Takashi Ohtsuka
Mitsutomo Kohno
Masafumi Kawamura
Hiroaki Nomori
author_facet Yoshikane Yamauchi
Yotaro Izumi
Kohei Hashimoto
Hideki Yashiro
Masanori Inoue
Seishi Nakatsuka
Taichiro Goto
Masaki Anraku
Takashi Ohtsuka
Mitsutomo Kohno
Masafumi Kawamura
Hiroaki Nomori
author_sort Yoshikane Yamauchi
title Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.
title_short Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.
title_full Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.
title_fullStr Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.
title_full_unstemmed Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.
title_sort percutaneous cryoablation for the treatment of medically inoperable stage i non-small cell lung cancer.
publisher Public Library of Science (PLoS)
publishDate 2012
url https://doaj.org/article/40f66a6ca3fd45b0935a10bd0cf3bbb0
work_keys_str_mv AT yoshikaneyamauchi percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT yotaroizumi percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT koheihashimoto percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT hidekiyashiro percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT masanoriinoue percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT seishinakatsuka percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT taichirogoto percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT masakianraku percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT takashiohtsuka percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT mitsutomokohno percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT masafumikawamura percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
AT hiroakinomori percutaneouscryoablationforthetreatmentofmedicallyinoperablestageinonsmallcelllungcancer
_version_ 1718423468457852928